Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Tobevibart · VIR-3434

Monoclonal antibody · developed by Vir Biotechnology

Phase 3 Most advanced trial
VIR Developer
2 Registered trials

What is Tobevibart?

Tobevibart (VIR-3434) is an antibody given by subcutaneous injection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
VIR-3434
Drug type
Monoclonal antibody
Therapy area
Gastroenterology, Infectious disease
Developer
Vir Biotechnology, Inc. (VIR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
PL93ZHC4L3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07128550 Phase 3 Viral Hepatitis Active not recruiting VIR
NCT05461170 Phase 2 Hepatitis D, Chronic Active not recruiting VIR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hepatitis D, ChronicViral Hepatitis

More from Vir Biotechnology

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the VIR page.

Follow VIR, the company behind Tobevibart

See VIR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VIR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.